Navigation Links
Cheaper drugs, vaccines forecast as collaborations grow between developing countries' biotech firms
Date:5/10/2010

t be expected to do everything on their own, according to the study.

Governments in the south need to better integrate south-south collaborations into their innovation policies and provide support to joint activities of firms from different developing countries. International organizations and philanthropic organizations engaged in promoting global health need to pay attention to the power of such south-south engagement in providing affordable health products.

"What is actually needed is a model of north-south-south collaboration, which harnesses the appropriate learning between developing countries and the technological and financial strengths of the North", says co-author Dr. Abdallah Daar of the MRC.

"There is considerable potential for firms in developing countries to be more cost effective than those in developed countries, providing health products that can reach more poor people in the developing world," he adds. "If successful, south-south collaboration increases capacity in science-intensive fields, improves the ability of developing countries to address their own problems, and contributes to economic development and quality of life in developing countries."

Although collaborations in science and technology have been high on the agendas of developing countries since the 1960s there has been little study of such collaborations and none at all into the health biotech sector until now.

Of the 288 health biotech firms that responded to the MRC survey, 27% reported south-south and south-north collaborations. South-north collaboration still dominates, with over half (53%) of the firms reporting collaborations with developed countries.

The study also determined that the vast majority (near 90 percent) of south-south collaborations relied on formal arrangements that ranged from supply agreements, to R&D cooperation and licensing agreements,to marketing and distribution agreements.

Cost and risk re
'/>"/>

Contact: Terry Collins
terrycollins@rogers.com
416-538-8712
McLaughlin-Rotman Centre for Global Health
Source:Eurekalert

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Hybrid computer materials may lead to faster, cheaper technology
2. Cheaper materials could be key to low-cost solar cells
3. Stanford researchers find a quicker, cheaper way to sort isotopes
4. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
5. Amazing Treatment Relieves Serious Back Pain Without Dangerous Drugs, Injections or Surgery!
6. New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents
7. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
8. Emergence of Cancer Vaccines Will Be the Key Factor Driving the Pancreatic Cancer Drug Market to More Than Double by 2016
9. Vaccines are Likely to Cause Insulin Dependent Diabetes in Over 2% of Children With a Strong Family History of Insulin Dependent Diabetes, New Data Indicates
10. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
11. PharmAthene Closes Acquisition of Avecia Biodefense Vaccines Business Unit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013 PuraMed BioScience ... and marketer of over-the-counter (OTC) medicinal and healthcare ... opinion on the company based on low market ... , Non-Prescription, All Natural Product to Treat Migraine ... Outperforms #1 Prescription Competitor , Currently Available ...
(Date:5/23/2013)... 23, 2013  Saddleback Memorial Medical Center in ... first hospital on the West Coast to perform a ... option provides women with a state-of-the-art, minimally invasive approach ... Winter , M.D., a highly regarded ... director of minimally invasive surgery at Saddleback Memorial, led ...
(Date:5/23/2013)... -- Northwest Biotherapeutics (NASDAQ: NWBO ) (NW ... immune therapies for solid tumor cancers, announced today that ... Society Of Clinical Oncology (ASCO) meeting in ... immune therapy.  (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO ) ... conference focused on clinical treatment of cancer, with attendance ...
(Date:5/23/2013)... Korea , May 23, 2013 ... SillaJen, Inc., a private biotherapeutics and contract research ... biological products for cancer, announced today a publication ... patients treated with the oncolytic and immunotherapeutic vaccinia ... This research was published in the May 15 ...
Breaking Biology Technology:PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 3
... Oct. 27 eBioscience Corporation today announced that ... Bender MedSystems GmbH in an all cash transaction. ... high profile immunology and oncology products including the ... life sciences and diagnostics markets. , "Bender MedSystems ...
... Medivation, Inc. (Nasdaq: MDVN) today announced that it will ... October 27, to discuss partnering plans for MDV3100, Medivation,s investigational ... treatment of prostate cancer. , Teleconference/Webcast Details ... October 27, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific ...
... Champions Biotechnology, Inc. (OTC Bulletin ... aimed at accelerating the development and enhancing the value ... Biotech Oncology Research & Development, a Division of Janssen ... oncology therapeutic in Champions, Biomerk Tumorgraft(TM) platform. ...
Cached Biology Technology:eBioscience Acquires Bender MedSystems; Business Combination Adds Cutting-Edge Product Lines and Expands International Operations 2eBioscience Acquires Bender MedSystems; Business Combination Adds Cutting-Edge Product Lines and Expands International Operations 3Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM) 2Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM) 3
(Date:5/23/2013)... School of Public Health at Emory University, along ... have received a $4 million grant over four ... University (Health and Exposome Research Center: Understanding Lifetime ... grant awarded in the United States. , ... Institute of Environmental Health Sciences (NIEHS) of the ...
(Date:5/23/2013)... undergo surgery or harsh treatments because science fails ... forms of the disease. Researchers at Case Western ... developing technology that allows patients to safely choose ... or take drastic measures. , The project is ... of biomedical engineering at Case Western Reserve and ...
(Date:5/23/2013)... Frontiers, one of the world,s largest and fastest ... new journal, Frontiers in Bioengineering and Biotechnology ... all specialties, Frontiers in Bioengineering and Biotechnology ... diverse and emerging bioengineering and biotechnology research to ... in Bioengineering and Biotechnology will provide an ...
Breaking Biology News(10 mins):Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3Using big data to identify prostate cancers and best treatments 2Using big data to identify prostate cancers and best treatments 3Frontiers launches new open-access journal in Bioengineering and Biotechnology 2
... a cabbage-eating moth may one day provide a safer, target-specific ... , They compared the ability of the four best-characterized jumping ... and produce a desired change, such as making the cell ... piggyBac transposon was five to 10 times better than the ...
... the largest HIV/AIDS therapy studies conducted to date ... therapy more than doubles the risk of AIDS ... the Mailman School of Public Health and Harlem ... known as Strategies for Management of Anti-Retroviral Therapies, ...
... may be placing their unborn children at increased risk ... study of construction workers in the Netherlands, conducted in ... links low birth weight and birth defects to paternal, ... and cleansers. , The study, although preliminary in its ...
Cached Biology News:Jumping gene could provide non-viral alternative for gene therapy 2Jumping gene could provide non-viral alternative for gene therapy 3Study shows interruption of antiretroviral therapy increases risk of disease and death 2Study shows interruption of antiretroviral therapy increases risk of disease and death 3Solvent exposure linked to birth defects in babies of male painters 2
MMP-20 Immunogen: Activated recombinant human MMP-2 Storage: -20 C, Avoid Freeze/Thaw Cycles...
Anti-Rsk2/MAPKAP Kinase 1b, #0 SK2/MAPKAP K1 beta Smartpool&t 3T3 cell lysate Non-specific Control Pool , #D 1X Universal Buffer...
Request Info...
Assay Kit formatted for flow cytometric detection of levels of phosphorylated histone H2A.X....
Biology Products: